Article
Oncology
Sara Soltanzadeh, Arefeh Saeedian, Reza Ghalehtaki, Mohsen Ayati, Mohammadreza Nowroozi, Peiman Haddad, Mahdieh Shafiee Sabet, Amin Kheirolahi
Summary: This study evaluated the feasibility, tolerance, and efficacy of concurrent chemoradiotherapy using cisplatin and capecitabine in patients with muscle-invasive bladder cancer. The results showed good tolerability and promising efficacy. Further studies are warranted to investigate the use of this combination in the treatment of bladder cancer.
CLINICAL GENITOURINARY CANCER
(2023)
Article
Health Care Sciences & Services
Jiaqiang Zhang, Shyh-Chyi Chang, Ming-Feng Chiang, Kuo-Chin Chiu, Szu-Yuan Wu
Summary: This study showed that among patients with MIBUC undergoing TURBT followed by CCRT for bladder preservation, current smokers with smoking-related COPD had significantly worse survival outcomes compared to nonsmokers without COPD. Additionally, hospitalization frequency for COPD with acute exacerbation within 1 year before CCRT was strongly associated with higher mortality in these patients.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Oncology
Nikhil V. Kotha, Abhishek Kumar, Tyler J. Nelson, Edmund M. Qiao, Alex S. Qian, Rohith S. Voora, Rana R. Mckay, Brent S. Rose, Tyler F. Stewart
Summary: This study suggests that a short-term delay in definitive therapy may not affect long-term outcomes for patients with MIBC undergoing CRT. It provides information to aid patients and clinicians navigate the unique challenges of MIBC care in both pandemic and non-pandemic times.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2022)
Review
Andrology
Xinxiang Fan, Wang He, Jian Huang
Summary: In recent years, less-invasive bladder-sparing trimodal therapy (TMT) has been increasingly used for selected patients with muscle-invasive bladder cancer (MIBC) who are unfit for or decline radical cystectomy (RC). This review summarizes the current evidence and future perspectives of bladder-sparing therapy for MIBC. TMT is a well-tolerated and curative alternative to RC for selected patients with localized MIBC, and the emergence of immunotherapy may further improve its effectiveness.
TRANSLATIONAL ANDROLOGY AND UROLOGY
(2023)
Review
Andrology
Xinxiang Fan, Wang He, Jian Huang
Summary: In recent years, the use of less-invasive bladder-sparing trimodal therapy (TMT) for selected patients with muscle-invasive bladder cancer (MIBC) who are unfit for radical cystectomy (RC) has been increasing. This review summarizes the current evidence and future perspectives of bladder-sparing therapy for MIBC. Combination therapy is more effective than monotherapy, and radiotherapy alone has poorer outcomes compared to chemoradiotherapy. Appropriate patient selection and a multi-disciplinary approach are crucial for successful bladder-sparing therapy.
TRANSLATIONAL ANDROLOGY AND UROLOGY
(2023)
Article
Oncology
Furkan Dursun, Ahmed Elshabrawy, Hanzhang Wang, Shenghui Wu, Michael A. Liss, Dharam Kaushik, Daniel Grosser, Robert S. Svatek, Ahmed M. Mansour
Summary: The study found that among NMIBC patients with variant histologies, those who underwent radical cystectomy had better overall survival for sarcomatoid, squamous, glandular, and neuroendocrine variants compared to those who had bladder preservation therapy, but this survival benefit was not observed in patients with micropapillary variant.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2022)
Article
Genetics & Heredity
Fangming Wang, Xiying Dong, Feiya Yang, Nianzeng Xing
Summary: The study aimed to characterize the mutation spectra of non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC) in the Chinese population and identify potential therapeutic targets. The results showed different gene mutational characteristics and signatures between NMIBC and MIBC, with a higher frequency of DNA-damage repair gene mutations in MIBC.
FRONTIERS IN GENETICS
(2022)
Article
Immunology
Chao Xu, Wen Zou, Lei Zhang, Ran Xu, Yuan Li, Yeqian Feng, Runtian Zhao, Yinhuai Wang, Xianling Liu, Jingjing Wang
Summary: A retrospective analysis revealed that bladder sparing therapy with PD-1 inhibitor in combination with radiotherapy or chemoradiotherapy is feasible, safe, and highly effective for MIBC patients who were unfit or unwilling to undergo radical cystectomy.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Weizhuo Wang, Xi Zhang, Silin Jiang, Peng Xu, Kang Chen, Kai Li, Fei Wang, Xiang Le, Ke Zhang
Summary: This study aimed to construct a prognostic model based on differential gene expression between muscular and non-muscular invasive bladder cancer (BCa), and to investigate the prognosis of BCa patients. BCa patient data from GEO and TCGA databases were analyzed, and single-cell sequencing and microarray data were used to validate the differential gene expression. The prognostic model showed accuracy and validity, and S100A9 may be a better prognostic marker and therapeutic target for BCa.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Sagar A. Patel, Yuan Liu, Abhishek A. Solanki, Brian C. Baumann, Jason A. Efstathiou, Ashesh B. Jani, Albert J. Chang, Benjamin Fischer-Valuck, Trevor J. Royce
Summary: This study found that the use of pelvic lymph node radiation has increased in bladder-sparing chemoradiation therapy for muscle-invasive bladder cancer. However, for patients without lymph node metastasis, the use of pelvic lymph node radiation may not impact long-term survival outcomes.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2023)
Review
Pharmacology & Pharmacy
Jillian Marie Walker, Padraic O'Malley, Mei He
Summary: Muscle invasive bladder cancer (MIBC) is a subtype of bladder cancer with a high risk of metastasis and death. Current diagnostic methods include urologic evaluation, CT scan, urinalysis, and cystoscopy. However, these invasive procedures carry risks and potential health concerns. Exosomes, as a novel source of biomarkers, show promise in addressing some of the limitations of urine cytology. This review provides an overview of MIBC, current urine cytology methods, the role of exosomes, and their potential as a diagnostic tool.
Review
Urology & Nephrology
Philipp Maisch, Alex Koziarz, Jon Vajgrt, Vikram Narayan, Myung Ha Kim, Philipp Dahm
Summary: Blue-light enhanced transurethral resection of bladder tumor (TURBT) may have a positive impact on the risk of disease recurrence and progression in non-muscle-invasive bladder cancer (NMIBC). However, the relevance of this risk reduction depends on the baseline risk of patients. There is no evidence of an increase in severe surgical complications with blue-light cystoscopy compared to white-light TURBT.
Article
Oncology
Stephan Degener, Nici Markus Dreger, Daniel Goedde, Judith Dotse, Stephan Roth, Hans Juergen Heppner, Rolf Lefering, Friedrich-Carl Von Rundstedt
Summary: Bladder cancer is common in the elderly, with up to 70% of geriatric patients with muscle-invasive bladder cancer not receiving curative treatment. A study analyzing elderly patients aged 75 years and above treated only with TURBT found that age, tumor size, extent of tumor resection, comorbidity index, and C-reactive protein level are independent predictors of survival.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2021)
Article
Oncology
Ashok Kumar, Manish Kumar, M. K. Semwal, Uday Singh, Nilima Mishra
Summary: Urinary bladder cancer is a significant global health issue, with high incidence and mortality rates. This study aimed to evaluate the treatment outcomes of conserving the bladder using a bladder preservation protocol in medically and surgically inoperable muscle-invasive bladder cancer. The results showed promising survival rates and outcomes in a resource-constrained setting.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
(2023)
Review
Oncology
Camilla De Carlo, Marina Valeri, Devin Nicole Corbitt, Miriam Cieri, Piergiuseppe Colombo
Summary: This review summarizes the recent evidence on prognostic and predictive tissue biomarkers in non-muscle invasive bladder cancer (NMIBC), highlighting the importance of histological features and molecular events in predicting recurrence and progression. The review also emphasizes the potential of immunohistochemical evaluation as a cost-effective tool for clinical practice.
FRONTIERS IN ONCOLOGY
(2022)